The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. [electronic resource]
Producer: 20200930Description: 4761 p. digitalISSN:- 2045-2322
- Aged
- Antineoplastic Agents -- pharmacology
- CD4-Positive T-Lymphocytes -- drug effects
- Cell Line, Tumor
- Heterocyclic Compounds, 3-Ring -- pharmacology
- Humans
- Immunotherapy -- methods
- Male
- Middle Aged
- PC-3 Cells
- Prostatic Neoplasms -- drug therapy
- T-Lymphocytes -- cytology
- Tankyrases -- antagonists & inhibitors
- Wnt Proteins -- antagonists & inhibitors
- Wnt Signaling Pathway -- drug effects
- beta Catenin -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.